National Institute for Health and Care Excellence

National Institute for Health and Care Excellence
Name	National Institute for Health and Care Excellence
Formation	1999
Type	Non-departmental public body
Headquarters	London
Leader title	Chief Executive
Parent organisation	Department of Health and Social Care

National Institute for Health and Care Excellence

The National Institute for Health and Care Excellence provides evidence-based guidance and advice for NHS England, NHS Scotland, NHS Wales, Scottish Parliament, Welsh Government commissioners and clinicians on the clinical and cost effectiveness of health technologies, clinical practice and public health interventions. Founded at the turn of the 21st century amid reforms associated with Tony Blair, Gordon Brown, Kenneth Clarke and health policy debates in the United Kingdom, the agency has influenced policy across United Kingdom devolved administrations, interacted with regulators like the Medicines and Healthcare products Regulatory Agency and engaged with international bodies including the World Health Organization, European Medicines Agency and Organisation for Economic Co-operation and Development.

History and formation

The institute originated from proposals in papers by Sir Derek Wanless, the Cooksey Report, and the 1997 health reform agenda championed by Frank Dobson and later implemented under Alan Milburn and John Reid. It was established after consultations involving Royal Colleges, British Medical Association, King's Fund, Nuffield Trust, Academy of Medical Royal Colleges, Wellcome Trust and the Health Select Committee. Early years saw governance links with the Department of Health and Social Care and scrutiny from committees chaired by MPs such as Margaret Hodge and Tony Wright. Predecessor advisory arrangements included expert panels used during the tenure of Kenneth Barker at health policy think tanks and built on methodologies advanced by researchers at University College London, Imperial College London, University of Oxford, University of Cambridge, London School of Hygiene & Tropical Medicine and University of Edinburgh.

Role and functions

The institute appraises medicines, devices and diagnostics through technology appraisal programmes and develops clinical guidelines via programmes comparable to processes at the Scottish Medicines Consortium and international counterparts like the Canadian Agency for Drugs and Technologies in Health, Institute for Clinical and Economic Review and Haute Autorité de Santé. It advises on public health interventions relevant to Public Health England (now part of UK Health Security Agency and Office for Health Improvement and Disparities), social care questions linked to Care Quality Commission inspections, and specialised services historically overseen with partners including NHS England Specialised Commissioning and regional bodies such as Clinical Commissioning Groups and Integrated Care Systems. Methodologically it uses health economics tools developed alongside researchers at MRC Clinical Trials Unit, National Institute for Health Research, Wellcome Trust Sanger Institute and modelling groups associated with London School of Hygiene & Tropical Medicine and University of York.

Guidance and publications

The institute publishes technology appraisals, clinical guidelines, public health guidance, quality standards, diagnostics guidance, and evidence summaries that intersect with outputs from Cochrane Collaboration, National Institute for Health Research, NICE Guideline Development Group panels, and professional guidance from Royal College of Physicians, Royal College of General Practitioners, Royal College of Surgeons, Royal College of Psychiatrists and specialty societies like British Cardiovascular Society, British Thoracic Society and British Association of Dermatologists. Landmark guidance on treatments has referenced trials published in journals such as The Lancet, BMJ, New England Journal of Medicine, JAMA and author groups including Cochrane Reviews and guideline committees chaired by figures associated with NHS Confederation events. The institute’s technology appraisal decisions have affected market access for products by companies including GlaxoSmithKline, AstraZeneca, Pfizer, Roche, Novartis and Sanofi and diagnostics by firms like Siemens Healthineers and Roche Diagnostics.

Organisation and governance

Governance has involved advisory committees, independent appraisal committees and guideline development groups with involvement from academics linked to University of Manchester, University of Birmingham, University of Glasgow, University of Southampton, University of Leeds and Queen Mary University of London. Chairs and executives have engaged with ministers from Department of Health and Social Care and oversight by parliamentary scrutiny bodies such as the Health and Social Care Select Committee and Public Accounts Committee. External stakeholders include patient organisations like Macmillan Cancer Support, Cancer Research UK, Alzheimer's Society, Diabetes UK and professional bodies like British Medical Association and Royal Colleges. Legal accountability has intersected with judgments in courts such as the High Court of Justice and references in debates on Human Rights Act 1998 implications for rationing.

Funding and accountability

Funding is principally from grants administered by the Department of Health and Social Care and fee income from the life sciences sector, negotiated with pharmaceutical companies and medical device manufacturers represented by trade bodies including the Association of the British Pharmaceutical Industry and ABHI. Accountability mechanisms include annual reports to Parliament, audits by the National Audit Office, and financial oversight using frameworks comparable to those applied to non-departmental public bodies such as Arts Council England and Environment Agency. Public procurement and transparency obligations interact with freedom of information provisions overseen by the Information Commissioner's Office.

Impact and controversies

The institute’s recommendations have influenced practice in hospitals overseen by NHS trusts such as Guy's and St Thomas' NHS Foundation Trust, Oxford University Hospitals NHS Foundation Trust, and Great Ormond Street Hospital and stimulated debate in Parliament involving MPs including Jeremy Hunt and Dame Caroline Dinenage. Controversies have included disputes over cost-effectiveness thresholds, end-of-life criteria, patient access schemes negotiated with companies like NICE Patient Access Scheme-related arrangements, high-profile cases concerning orphan drugs and gene therapies involving firms such as Spark Therapeutics and Novartis, and legal challenges that referenced procurement rules and judicial review. Academic critique from centres including Institute for Fiscal Studies, Nuffield Trust, King's Fund and economists at University of York Centre for Health Economics has prompted methodological revisions and stakeholder consultations with charities including Royal Society for Public Health and patient groups like CARDIAC Risk in the Young.

Category:Health policy in the United Kingdom